|
Agent Type:
|
Synthetic; Small molecule;
|
|
Spectrum of activity:
|
Gram-positive & Gram-negative
|
|
Mechanism of action:
|
Unknown
|
|
Target Pathogen:
|
Active against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Streptococcus faecalis, and Clostridium perfringens
|
|
Description:
|
Synthetic compound; formulates as taurolidine heparin sodium solution to additionally reduce thrombosis
|
|
Institute where first reported:
|
Cormedix
|
|
Year first mentioned:
|
1977
|
|
Highest developmental phase:
|
Approved by FDA in 2023
|
|
Development status:
|
Approved
|